Presentation Information
[E4-6]Clinical Impact of 1L Therapeutic Strategies in BRAF V600E-Mutant Metastatic Colorectal Cancer
Shihwei Chiang1,2, Chia-Chang Yeh1, Feng-Fan Chiang1,3 (1.Taichung Veterans General Hospital, 2.Department of Nutrition, Chung Shan Medical University, 3.College of Humanities and Social Sciences, Providence University)
BRAF V600E-mutant metastatic colorectal cancer (mCRC) is aggressive and shows poor response to standard therapy. While targeted treatments show promise in trials, real-world data are limited. This retrospective study included 36 patients treated at Taichung Veterans General Hospital between 2018 and 2024. Patients received either chemotherapy alone, chemotherapy with anti-VEGF, or chemotherapy with BRAF/EGFR plus or minus MEK inhibitors. Primary endpoints were overall survival (OS) and progression-free survival (PFS), while secondary endpoints included objective response rate (ORR) and disease control rate (DCR). The chemo plus anti-VEGF group showed the longest OS at 21.2 months and PFS at 10.5 months. The highest ORR at 53.8% and DCR at 76.9% were seen in the BRAF-targeted group. Liver metastasis and ECOG performance status 2 or above were poor prognostic factors. Right-sided tumors were unexpectedly associated with better survival (hazard ratio 0.20, p<0.028). Use of later-line BRAF-targeted therapy may have contributed to prolonged OS.